Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Maintains $105 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on CRISPR Therapeutics (NASDAQ:CRSP) and maintained a price target of $105.
June 17, 2024 | 5:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on CRISPR Therapeutics and maintained a price target of $105.
The reiteration of an Overweight rating and a maintained price target of $105 by a reputable analyst is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100